

FOI 2593

18<sup>th</sup> September 2024

## **FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

I would be grateful if you could send me an extract of data from the hospital pharmacy database, showing quantities of medicines used. See specification below and I would be grateful if this can be supplied in Excel or .csv format.

Please include data for all hospitals in the Health and Social Care Trust.

### **Data on usage of medicines from the hospital pharmacy system**

Fields to include in the data extract from the hospital pharmacy database:

Field
Calendar year
Calendar month
Name of Health Board / Trust
Drug substance (INN name of drug) – See <i>Column C, Drug name</i>
Drug product pack name (substance name + strength + formulation)
Pack size
Quantity unit of measure (UOM)
Quantity issued – <i>quantity issued (Column G) is that of drug packsize (Column E)</i>

### **Filters**

Time period: 1<sup>st</sup> Mar 2024 to 30<sup>th</sup> Jun 2024, or the latest available month

#### **1. Drugs – severe asthma**

- Benralizumab (Fasenra) – not recorded
- Dupilumab (Dupixent) – not held
- Mepolizumab (Nucala) – not held
- Omalizumab (Xolair) – not held
- Reslizumab (Cinqaero) – not recorded
- Tezepelumab (Tezspire) – not recorded

#### **2. Drugs – breast cancer**

- Abemaciclib (Verzenios) – please see Attachment 1
- Palbociclib (Ibrance) – please see Attachment 1
- Ribociclib (Kisqali) – please see Attachment 1
- Alpelisib (Piqray) – not recorded

- **Fulvestrant (fulvestrant or Faslodex)** – please see Attachment 1

### 3. Drugs – prostate cancer

- **Abiraterone (Zytiga + generics)** – please see Attachment 2
- **Apalutamide (Erleada)** – not held
- **Cabazitaxel (Jevtana + generics)** – please see Attachment 2
- **Darolutamide (Nubeqa)** – please see Attachment 2
- **Enzalutamide (Xtandi)** – please see Attachment 2

### 4. Drugs – ovarian and endometrial cancers

- **Niraparib (Zejula)** – not recorded
- **Olaparib (Lynparza)** – please see Attachment 3
- **Rucaparib (Rubraca)** – not recorded
- **Dostarlimab (Jemperli)** – not recorded

**Time period: 1<sup>st</sup> Jan 2021 to 30<sup>th</sup> Jun 2024, or the latest available month:**

### 5. Drugs – myeloproliferative diseases

- **Momelotinib (Omjjara)** – not held
- **Ruxolitinib (Jakavi)** – please see Attachment 4
- **Fedratinib (Inrebic)** – please see Attachment 4
- **Ropeginterferon alfa-2b (Besremi)** – not recorded
- **Peginterferon alfa-2a (Pegasys)** – please see Attachment 4
- **Epoetin alfa (Eprex, Binocrit)** – not recorded
- **Epoetin beta (NeoRecormon, Mircera)** – please see Attachment 4
- **Epoetin zeta (Retacrit)** – not recorded

**Time period: 1<sup>st</sup> Jan 2021 to 30<sup>th</sup> Jun 2024, or the latest available month:**

### 6. Drugs – Lung cancer

- **Durvalumab** – please see Attachment 5
- **Osimertinib** – please see Attachment 5
- **Amivantamab** – not recorded
- **Atezolizumab** – please see Attachment 5
- **Nivolumab** – please see Attachment 5

### 7. Drugs – Haematology

- **Acalabrutinib** – please see Attachment 6
- **Ibrutinib** – please see Attachment 6
- **Obinutuzumab** – please see Attachment 6
- **Rituximab** – please see Attachment 6
- **Venetoclax** – please see Attachment 6
- **Zanubrutinib** – please see Attachment 6